Acitretin
- Generic Name
- Acitretin
- Brand Names
- Soriatane
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O3
- CAS Number
- 55079-83-9
- Unique Ingredient Identifier
- LCH760E9T7
- Background
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
- Indication
For the treatment of severe psoriasis in adults.
- Associated Conditions
- Keratinization disorders, Severe Psoriasis
- Associated Therapies
- -
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 129
- Registration Number
- NCT00003611
- Locations
- 🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸CCOP - Wichita, Wichita, Kansas, United States
🇺🇸CCOP - Carle Cancer Center, Urbana, Illinois, United States
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00002143
- Locations
- 🇺🇸
Beth Israel Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath